After 8-year Followup, Good News for the Self Expandable Valve

As the transcatheter aortic valve replacement (TAVR) gains ground in lower risk populations and with better survival rate, concern over its durability has grown. 

Buenas noticias a 8 años de seguimiento para la válvula autoexpandible

This study brings us data and good news on the first-generation self-expandable valve after quite a long follow up.

It included 990 inoperable or high-risk patients treated with CoreValve in 8 centers in Italy between 2007 and 2011. Mean global followup was 4.4 years, but it lasted 11 years. 

728 patients died within the 8-year followup period (78.3% mortality from Kaplan-Meier curve analyzis).

Most patients who survived after 8 years improved functional class after procedure and this improvement was maintained over time. 79.3% of surviving patients are still classified as FC ≤ II at 8 years.


Read also: Positive Outcomes of CoreValve Evolut in Large Population.


The echocardiograms showed no change in mean gradient (9 ± 4 mmHg at discharge vs 9 ± 5 mmHg at 8 years, p=0.495). Leaks also showed no change. 

Structural valve deterioration moderate to severe (according to 2017 EAPCI/ESC/EACTS criteria) was 3% and 1.6%, respectively in surviving patients at 8 years.

Conclusion

While still debating TAVR durability at long term, this study provides promising data and evidence on the first generation self-expandable CoreValve at 8 years.

Original Title: Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis.

Reference: Luca Testa et al. European Heart Journal (2020) 0, 1–11. doi:10.1093/eurheartj/ehz925.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...